23 / 06 / 2020
On 23 June 2020, the Innovative Medicines Initiative (IMI) launched the last Calls for proposals (IMI2 – Call 22 and IMI2 – Call 23) under the IMI2 programme, which focus on tackling cancer through Artificial Intelligence (AI), antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, the return of clinical trial data to participants, and patient adherence.
IMI will contribute €59 million to the projects funded under the Calls. These funds come from Horizon 2020 Programme and will support the participation in the projects of organisations such as universities, small and medium-sized enterprises, and patient groups. The submission deadline (for full proposals for IMI2 – Call 22, and short proposals for IMI2 – Call 23) is 29 September 2020.